Treatment
Pralatrexate clinical trials
We’re tracking 6 recruiting studies that include Pralatrexate, each written for real people, not researchers, below.
Recruiting studies
- NCT03161223RecruitingPhase 1/Phase 2
Durvalumab plus other medicines for peripheral T-cell lymphoma
This early-phase study tests how well durvalumab (an immune therapy) works with other medicines—either with or without pralatrexate, romidepsin, and oral 5-azacitidine—to treat peripheral T-cell lymphoma. It may help people with newly diagnosed or relapsed/refractory disease by strengthening the immune attack on the lymphoma.
Charlottesville, VirginiaAges 18 years+ - NCT06072131RecruitingPhase 3
Comparing belinostat or pralatrexate with chemotherapy for PTCL
This trial tests whether adding belinostat or pralatrexate to standard chemotherapy (CHOP) works better than CHOP alone for people newly diagnosed with peripheral T-cell lymphoma (PTCL). It aims to find a more effective first treatment option.
Clovis, CaliforniaAges 18 years+ - NCT07036133RecruitingPhase 1
Study of Pralatrexate in patients with advanced cancer and liver problems
This trial tests a drug called pralatrexate in people with advanced solid tumors or blood cancers, including those with different levels of liver function. The goal is to understand how the drug works in the body and how safe it is for patients with various degrees of liver impairment.
Cerritos, CaliforniaAges 18 years+ - NCT07225985RecruitingPhase 1/Phase 2
Pralatrexate, bendamustine, and radiation before donor stem cell transplant for T-cell lymphoma
This trial tests a combination of two chemotherapy drugs (pralatrexate and bendamustine) plus total-body radiation before a donor stem cell transplant for people with T-cell lymphoma that has come back or hasn't responded to treatment. The goal is to see if this approach can help destroy the lymphoma and allow the donor cells to take hold safely.
Seattle, WashingtonAges 18 years+ - NCT04747236RecruitingPhase 2
Study of oral azacytidine plus romidepsin for relapsed T-cell lymphoma
This trial tests whether an oral drug (azacytidine) plus romidepsin works better than a standard “doctor’s choice” treatment for people with relapsed or refractory peripheral T-cell lymphoma. It’s for adults whose disease has come back or did not respond after prior treatment.
Long Beach, CaliforniaAges 18 years+ - NCT06561048RecruitingPhase 3
Soquelitinib vs standard care for relapsed or refractory T-cell lymphoma
This trial compares a new drug, soquelitinib, with standard treatments for peripheral T-cell lymphoma that has come back or not responded to previous therapy. It may help people who have had one to three prior treatments and are looking for a new option.
Duarte, CaliforniaAges 18 years+
What Pralatrexate is being studied for
Conditions with recruiting Pralatrexate studies.
Common questions
- Are there clinical trials studying Pralatrexate?
- Yes. Clin2 currently lists 6 recruiting studies that include Pralatrexate, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Pralatrexate trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Pralatrexate an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Pralatrexate or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.